- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01954771
SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD
A Prospective, Randomized, Controlled Study on Self-monitoring of Blood Glucose (SMBG) Protocols in Predicting Glucose Levels in Senior Patients With Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Beijing
-
Beijing, Beijing, Cina, 100029
- Capital Medical University Affiliated Beijing Anzhen Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Clinical diagnosis of type 2 diabetes
- Clinical diagnosis of coronary artery disease
- Age ≥65 years
- The blood glucose is controlled by diets and (or) oral hypoglycemic drugs
- BMI≤28 kg/m²
- Being able to monitor and record capillary glucose value by themselves at home
Exclusion Criteria:
- Diabetic ketoacidosis (DKA)
- Acute cardiovascular events
- Anemia
- Insulin treatment
- Incapable to perform SMBG at home
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore attivo: Control Group
Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods.
Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
|
Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes.
The expected duration of the trial is 12 weeks.
|
Comparatore attivo: SMBG-4 Group
Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day.
Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
|
Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes.
The expected duration of the trial is 12 weeks.
|
Comparatore attivo: SMBG-7 Group
Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day.
Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
|
Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively. SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes.
The expected duration of the trial is 12 weeks.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS)
Lasso di tempo: 12 weeks
|
The peak value:>16.7mmol/L(which
may precipitate ketosis),nadir:≤2.8mmol/L(Severe
hypoglycemia).
|
12 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The Correlation Study Between HbA1c and Glycemic Profiles of MBG (Mean Blood Glucose) From SMBG Protocols and CGMS
Lasso di tempo: 12 weeks
|
A correlation coefficient of 0.5 is defined as large effect size.(Cohen Jacob.Statistical power analysis for the the behavioral sciences.2nd
edition.Lawrence Erlbaum Associates.1988:80)
|
12 weeks
|
Number of Participants With Severe Hypoglycemia (≤50 mg/dL or 2.8mmol/L),Captured by SMBG Method and CGMS
Lasso di tempo: 12 weeks
|
Severe hypoglycemia is defined as glucose concentration of ≤2.8mmol/L (50 mg/dL).
|
12 weeks
|
HbA1c(%) at Endpoint
Lasso di tempo: 12 weeks
|
12 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Yingsheng Zhou, MD; PhD, Capital Medical University Affiliated Beijing Anzhen Hospital
Pubblicazioni e link utili
Pubblicazioni generali
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.
- Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009 Jan;32(1):187-92. doi: 10.2337/dc08-9026. Epub 2008 Dec 17. No abstract available. Erratum In: Diabetes Care. 2009 Apr;32(4):754.
- Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008 Feb;31 Suppl 2:S150-4. doi: 10.2337/dc08-s241.
- Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, Nerup J, Borch-Johnsen K, Witte DR; ADAG Study Group. HbA(1)(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia. 2011 Jan;54(1):69-72. doi: 10.1007/s00125-010-1918-2. Epub 2010 Oct 1.
- Lipska KJ, Krumholz H, Soones T, Lee SJ. Polypharmacy in the Aging Patient: A Review of Glycemic Control in Older Adults With Type 2 Diabetes. JAMA. 2016 Mar 8;315(10):1034-45. doi: 10.1001/jama.2016.0299.
- Wang P, Huang R, Lu S, Xia W, Sun H, Sun J, Cai R, Wang S. HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis. Cardiovasc Diabetol. 2015 Sep 22;14:124. doi: 10.1186/s12933-015-0285-1.
- Munshi MN, Segal AR, Slyne C, Samur AA, Brooks KM, Horton ES. Shortfalls of the use of HbA1C-derived eAG in older adults with diabetes. Diabetes Res Clin Pract. 2015 Oct;110(1):60-65. doi: 10.1016/j.diabres.2015.07.012. Epub 2015 Aug 3.
- Hoffman RM, Shah JH, Wendel CS, Duckworth WC, Adam KD, Bokhari SU, Dalton C, Murata GH; Diabetes Outcome in Veterans Study. Evaluating once- and twice-daily self-monitored blood glucose testing strategies for stable insulin-treated patients with type 2 diabetes : the diabetes outcomes in veterans study. Diabetes Care. 2002 Oct;25(10):1744-8. doi: 10.2337/diacare.25.10.1744.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie cardiache
- Malattia cardiovascolare
- Malattie vascolari
- Disturbi del metabolismo del glucosio
- Malattie metaboliche
- Arteriosclerosi
- Malattie arteriose occlusive
- Malattie del sistema endocrino
- Disfunsione dell'arteria coronaria
- Ischemia miocardica
- Malattia coronarica
- Diabete mellito
- Diabete mellito, tipo 2
Altri numeri di identificazione dello studio
- Z131100004013044
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Disfunsione dell'arteria coronaria
-
Tel-Aviv Sourasky Medical CenterCompletatoSoggetti consecutivi che sono idonei per una coronaria | Angioplastica di de Novo Lesion(s) in Native Coronary | Le arterie dovrebbero essere sottoposte a screening per l'idoneità. | Un numero totale di 200 pazienti che soddisfano la selezione | Criteri e disponibilità a firmare il consenso... e altre condizioniIsraele
Prove cliniche su SMBG
-
Abbott Diabetes CareTerminato
-
HealthPartners InstituteAbbott Diabetes Care; International Diabetes Center at Park NicolletCompletatoDiabete di tipo 2Stati Uniti
-
DexCom, Inc.CompletatoDiabete mellito, tipo 2Stati Uniti, Canada
-
Pusan National University HospitalSconosciutoObesità | Stato prediabetico | Monitoraggio continuo del glucosioCorea, Repubblica di
-
Medtronic DiabetesCompletatoDiabete mellitoFrancia, Germania, Israele, Italia, Slovenia, Svezia, Regno Unito
-
Kangbuk Samsung HospitalDexCom, Inc.ReclutamentoDiabete mellito | Prediabete | Malattia cardiacaCorea, Repubblica di
-
Chinese University of Hong KongSconosciutoDiabete con malattia renale cronica diabetica (diagnosi)Hong Kong
-
University of North Carolina, Chapel HillPatient-Centered Outcomes Research InstituteCompletatoDIABETE MELLITO NON INSULINO-DIPENDENTE, 2 (disturbo)Stati Uniti
-
Abbott Diabetes CareCompletato
-
Abbott Diabetes CareCompletatoDiabete mellitoRegno Unito